WT1 peptide-pulsed dendritic cell therapy for wet age-related macular degeneration

未提供0 个研究点目标入组 10 人开始时间: 2021年11月25日最近更新: 2025年6月10日

试验速览

暂无简介。

•Clinically diagnosed with wet age-related macular degeneration
•The name of the disease in 1) has been announced.
•HLA type is HLA-A (A * 2402, A * 0201, A * 0206), HLA-DR (DRB1 * 0101, DRB1 * 0405, DRB1 * 0802, DRB1 * 0803, DRB1 * 0901, DRB1 * 1201, DRB1 * 1403, DRB1 * 1501, DRB1 * 1502, DRB5 * 0102), HLA-DP (DPB1 * 0201, DPB1 * 0202, DPB1 * 0402, DPB1 * 0501, DPB1 * 0901), HLA-DQ (DQB1 * 0301, One of DQB1 * 0302, DQB1 * 0401, DQB1 * 0501, DQB1 * 0601, DQB1 *
•Outpatient visits are possible according to the research implementation schedule.
•Patient without treatment for cancer.
•Over 50 years of age
•Patients who retain the functions of major organs (confirmed by pre-registration examination).
•Written consent from the patient has been obtained for participation in this study.
•Meet the apheresis eligibility criteria for dendritic cell production

•Have an uncontrolled infectious disease
•Serious complications: malignant hypertension, severe congestive heart failure, severe coronary failure, unstable edema or myocardial infarction within 12 months, severe arrhythmia requiring medication and more than 2nd degree Patients with conduction abnormalities such as AV block, liver cirrhosis, uncontrolled diabetes, pulmonary fibrosis, interstitial pneumonia, marked peripheral edema, etc. active infections, active hepatitis B
•Patients who are considered unsuitable for participation in this clinical trial due to complications or whose safety may be compromised due to serious medical events.
•Cases in which antitumor treatment such as chemotherapy / radiochemotherapy was performed within 1 year
•Have serious complications
•Patients with myelodysplastic syndrome, myelodysplastic / myeloproliferative disorders and chronic myelogenous leukemia
•History of severe drug hypersensitivity (excluding iodine contrast media)
•Patients with severe mental illness
•Patients with autoimmune disease
•Patients with a history of allergies to OK-432 and penicillin G
•Pregnant or lactating women
•Pregnant women who are not willing to contracept

Safety(Adverse event rate,Rate of serious adverse events)

发起方

未提供